Claritev Management
Management criteria checks 3/4
Claritev's CEO is Travis Dalton, appointed in Mar 2024, has a tenure of 2.25 years. total yearly compensation is $10.20M, comprised of 8.1% salary and 91.9% bonuses, including company stock and options. directly owns 1% of the company’s shares, worth $5.05M. The average tenure of the management team and the board of directors is 2 years and 5.5 years respectively.
Key information
Travis Dalton
Chief executive officer
US$10.2m
Total compensation
| CEO salary percentage | 8.09% |
| CEO tenure | 2.3yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Narrative Update • Jun 11
CTEV: New Contracts And Management Changes Will Drive Future Upside Potential
Claritev's updated analyst price target has moved lower by about $3 to $36.83, as analysts factor in slightly softer revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple. This is partly offset by higher projected profit margins and recent Street targets that range from $32 to $61.
Narrative Update • May 27
CTEV: Early FY26 Contracts And DOJ Probe Will Shape Execution Outlook
Analysts have lifted their Claritev price target to $40 from $21, pointing to stronger early FY26 contract wins and new customer additions as key drivers behind the updated fair value estimate of $22 and a higher future P/E assumption. Analyst Commentary Recent research points to improving sentiment around Claritev, with analysts highlighting early FY26 contract wins of US$44m in annual contract value and six new customer additions as key supports for the higher fair value estimate and revised P/E assumption behind the US$40 price target.Narrative Update • May 05
CTEV: Volume Resilience And 2026 Buybacks Will Support Future Upside
Claritev's analyst fair value has been revised from $42.75 to $39.80 as analysts factor in slightly lower profit margin assumptions and a small reset in future P/E expectations, in line with recent price target trims from several firms following updated guidance and investment plans. Analyst Commentary Street research on Claritev has shifted toward more conservative assumptions on margin, revenue mix and investment timing, while still highlighting areas where execution could support the current valuation over time.Seeking Alpha • Apr 20
Claritev: Compounding Debt Meets Legacy Business Stabilization (Rating Upgrade)
Summary Claritev is upgraded to 'Hold' after a 32% decline, with the short thesis largely played out. Legacy business revenues are stabilizing, showing 6.2% YoY Q4 growth and accelerating full-year growth, despite margin pressure from regulatory changes. BenInsights' failed pivot is now fully reflected in CTEV’s valuation; any positive developments could act as catalysts. CTEV’s $4.6B debt load and negligible free cash flow keep valuation unattractive, with a 9.2x EV/EBITDA multiple deemed expensive for its risk profile. Read the full article on Seeking AlphaNarrative Update • Apr 20
CTEV: Entrenched Payer Role And 2026 Buyback Capacity Will Support Upside
Claritev's analyst price target has been reset lower, with the model's fair value estimate moving from $44.75 to $42.75 as analysts factor in reduced formal targets from Citi, Guggenheim, and Wells Fargo, along with updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Claritev has coalesced around lower price targets, but the tone is mixed, with analysts highlighting both upside drivers and areas where execution and guidance keep them cautious.Narrative Update • Apr 05
CTEV: Entrenched Position And Buybacks Will Support Volume Driven Earnings Power
Analysts cut the Claritev price target to $21, with updated models reflecting slightly different revenue growth, profit margin, and future P/E assumptions following recent guidance and sector research. Analyst Commentary Recent Street research on Claritev points to a reset in expectations, with several bearish analysts cutting price targets and highlighting execution and balance sheet risks, even as ratings in the sample remain unchanged.Narrative Update • Mar 22
CTEV: Entrenched Position And Buybacks Will Support More Sustainable Future Margins
Analysts have reduced the Claritev price target to $21 from $33, reflecting updated expectations for slower revenue growth, slightly lower profit margins, and a lower future P/E multiple, even as they cite solid recent results and continued investment in growth initiatives. Analyst Commentary Recent research updates show a clear reset in expectations for Claritev, with multiple firms cutting price targets while generally maintaining existing ratings.Narrative Update • Mar 07
CTEV: Entrenched Payer Role And 2026 Guidance Reset Will Support Upside
The analyst price target for Claritev has been reduced from $57.25 to $44.75. Analysts cited lower revenue growth and profit margin assumptions, as well as a revised future P/E expectation following recent price target cuts from multiple firms.Narrative Update • Feb 21
CTEV: Entrenched Position And Deleveraging Will Support More Sustainable Future Margins
Claritev's analyst price target has been reset lower to $63, down from $80, as analysts factor in a slightly lower future P/E assumption of 9.87x. They also note that the company remains an entrenched vendor with accelerating revenue but elevated leverage that can weigh on valuation.Narrative Update • Feb 06
CTEV: Entrenched Payer Position And Deleveraging Will Support Future Upside
Analysts have trimmed their fair value estimate for Claritev to $57.25 from $85, citing updated Street price targets in the $33 to $63 range and reduced future P/E assumptions, while also acknowledging steady revenue growth and margin expectations. Analyst Commentary Bullish and cautious views on Claritev are both in play, and that split is driving a wide range of price targets and valuation opinions.Narrative Update • Jan 23
CTEV: Revenue Recovery And Deleveraging Will Support More Sustainable Future Margins
Narrative Update Opening Analysts have trimmed their fair value estimate for Claritev from $80 to $33, citing a lower Street price target that ranges from $63 at the high end to $33, and a view that stronger revenue growth and steady margins are now balanced by a less premium future P/E and concerns about elevated leverage. Analyst Commentary Recent research updates on Claritev highlight a split view, with some firms still constructive on the long term while taking down price targets and others starting coverage at more neutral levels.Analysis Article • Jan 18
Claritev Corporation (NYSE:CTEV) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Claritev Corporation ( NYSE:CTEV ) share price has dived 26% in the last...Narrative Update • Jan 09
CTEV: Best In Class Margins And Deleveraging Efforts Will Support Upside
Analysts have raised their average price target on Claritev to US$74 from US$55, citing confidence in the company's ability to accelerate growth while maintaining strong margins, even as some remain cautious about leverage and valuation. Analyst Commentary Recent research paints a mixed picture around Claritev, with bullish analysts highlighting growth potential and margin strength, while more cautious voices focus on balance sheet risk and how much optimism is already reflected in the share price.Narrative Update • Dec 25
CTEV: Mid Single Digit Revenue Recovery Will Support Best In Class Margins
Analysts have raised their price target on Claritev from 55 dollars to 80 dollars, citing increased confidence that the company can reaccelerate to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Recent research notes highlight a more constructive stance on Claritev's long term prospects, with the latest upgrade reflecting greater confidence in management's roadmap to restore sustainable growth while preserving strong profitability.Narrative Update • Dec 11
CTEV: Best-In-Class Margins Will Support Return To Mid-Single-Digit Expansion
Claritev's analyst price target has been raised to $74 from $55, as analysts cite growing confidence that the company can return to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Bullish Takeaways Bullish analysts view the higher $74 target as reflecting renewed confidence in Claritev's ability to reaccelerate revenue growth while preserving margin discipline.Narrative Update • Nov 27
CTEV: Upgraded Buy Rating Will Drive Growth Momentum and Margin Strength
Analysts have raised Claritev’s price target from $80 to $85, reflecting renewed confidence in the company’s accelerating growth and its ability to maintain strong margins. Analyst Commentary Analyst sentiment around Claritev continues to evolve as the company demonstrates a strong execution track record and new growth initiatives.Narrative Update • Nov 06
CTEV: Upgraded Buy Rating Will Drive Renewed Momentum Through 2026
Narrative Update on Claritev Analysts have raised Claritev's price target from $55 to $74, citing increased confidence in the company's plan to accelerate growth and maintain industry-leading margins. Analyst Commentary Following the recent upgrade and price target revision, analysts have shared a range of insights on Claritev’s prospects and execution trajectory.Analysis Article • Nov 01
Improved Revenues Required Before Claritev Corporation (NYSE:CTEV) Stock's 35% Jump Looks Justified
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 35% gain in the last month alone...Narrative Update • Oct 23
Analysts Boost Claritev Valuation Amid Growth Optimism and Strategic Developments
Analysts have raised Claritev's fair value estimate from $70.50 to $80.00. They cite growing confidence in the company's accelerated revenue growth outlook and sustained margins following the recent price target upgrade.Analysis Article • Sep 09
Claritev Corporation's (NYSE:CTEV) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Despite an already strong run, Claritev Corporation ( NYSE:CTEV ) shares have been powering on, with a gain of 27% in...Narrative Update • Aug 08
Digital Transformation And AI Adoption Will Drive Global Healthcare Expansion
Claritev’s future P/E has increased markedly while net profit margin has declined, indicating higher valuation despite weaker profitability, yet the consensus price target remains unchanged at $49.50. What's in the News Claritev updated full-year 2025 revenue guidance to flat to +2% versus 2024.Analysis Article • Jul 30
Claritev (NYSE:CTEV) Use Of Debt Could Be Considered Risky
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jul 09
Claritev Corporation's (NYSE:CTEV) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 25% gain in the last month alone...New Narrative • May 30
AI And Global Partnerships Will Reshape Personalized Medicine
AI-powered analytics, digital transformation, and global expansions position Claritev to monetize higher-value healthcare solutions and tap into growing, aging populations.Analysis Article • May 15
Claritev Corporation (NYSE:CTEV) Shares Fly 30% But Investors Aren't Buying For Growth
Claritev Corporation ( NYSE:CTEV ) shareholders would be excited to see that the share price has had a great month...Analysis Article • Mar 20
Little Excitement Around Claritev Corporation's (NYSE:CTEV) Revenues As Shares Take 28% Pounding
Claritev Corporation ( NYSE:CTEV ) shares have retraced a considerable 28% in the last month, reversing a fair amount...Analysis Article • Feb 03
There's No Escaping MultiPlan Corporation's (NYSE:MPLN) Muted Revenues Despite A 29% Share Price Rise
MultiPlan Corporation ( NYSE:MPLN ) shares have continued their recent momentum with a 29% gain in the last month...Analysis Article • Dec 20
MultiPlan Corporation (NYSE:MPLN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Those holding MultiPlan Corporation ( NYSE:MPLN ) shares would be relieved that the share price has rebounded 28% in...Analysis Article • Dec 13
Here's Why MultiPlan (NYSE:MPLN) Is Weighed Down By Its Debt Load
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Oct 20
MultiPlan Corporation (NYSE:MPLN) Shares Fly 55% But Investors Aren't Buying For Growth
MultiPlan Corporation ( NYSE:MPLN ) shareholders are no doubt pleased to see that the share price has bounced 55% in...Analysis Article • Aug 18
MultiPlan Corporation (NYSE:MPLN) Not Doing Enough For Some Investors As Its Shares Slump 40%
To the annoyance of some shareholders, MultiPlan Corporation ( NYSE:MPLN ) shares are down a considerable 40% in the...Analysis Article • Jul 04
Little Excitement Around MultiPlan Corporation's (NYSE:MPLN) Revenues As Shares Take 46% Pounding
Unfortunately for some shareholders, the MultiPlan Corporation ( NYSE:MPLN ) share price has dived 46% in the last...Analysis Article • Jul 02
MultiPlan (NYSE:MPLN) Use Of Debt Could Be Considered Risky
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$287m |
| Dec 31 2025 | US$10m | US$825k | -US$284m |
| Sep 30 2025 | n/a | n/a | -US$342m |
| Jun 30 2025 | n/a | n/a | -US$663m |
| Mar 31 2025 | n/a | n/a | -US$1b |
| Dec 31 2024 | US$12m | US$654k | -US$2b |
Compensation vs Market: Travis's total compensation ($USD10.20M) is above average for companies of similar size in the US market ($USD2.57M).
Compensation vs Earnings: Travis's compensation has been consistent with company performance over the past year.
CEO
Travis Dalton (55 yo)
2.3yrs
Tenure
US$10,202,667
Compensation
Mr. Travis S. Dalton serves as the Chief Executive Officer at Benefits Science LLC. He serves as Chief Executive Officer and President of Claritev Corporation (formerly known as MultiPlan Corporation) sinc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 2.3yrs | US$10.20m | 1.0% $ 5.1m | |
| Executive VP & CFO | 1.8yrs | US$2.94m | 0.46% $ 2.3m | |
| Executive VP & COO | 2.3yrs | US$2.81m | 0.21% $ 1.1m | |
| Executive VP & Chief Digital Officer | 1.3yrs | US$1.80m | 0.71% $ 3.6m | |
| Senior VP & Chief Growth Officer | 1.7yrs | US$1.49m | 0.11% $ 581.4k | |
| Senior VP & Chief Accounting Officer | less than a year | no data | no data | |
| Senior Vice President of Treasury & Investor Relations | 2.4yrs | no data | no data | |
| Chief Legal Officer | 1.8yrs | no data | no data | |
| Chief Compliance & Chief Privacy Officer | less than a year | no data | no data | |
| Senior Vice President of Marketing & Communications | 3.4yrs | no data | no data | |
| Vice President of Strategy & Corporate Development | 3.6yrs | no data | no data | |
| Senior VP & Chief People Officer | 3.4yrs | US$1.10m | 0.062% $ 314.6k |
2.0yrs
Average Tenure
55yo
Average Age
Experienced Management: CTEV's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 1.5yrs | US$10.20m | 1.0% $ 5.1m | |
| Lead Independent Director | 5.7yrs | no data | no data | |
| Independent Director | 5.7yrs | US$303.35k | 0.12% $ 620.3k | |
| Independent Director | 5.4yrs | US$281.70k | 0.090% $ 455.2k | |
| Independent Director | 5.7yrs | US$265.00k | 3.06% $ 15.5m | |
| Independent Director | 5.7yrs | US$291.70k | 0.090% $ 456.7k | |
| Director | 4.3yrs | US$1.24m | 1.79% $ 9.1m | |
| Independent Director | 5.6yrs | US$299.23k | 0.092% $ 465.0k | |
| Independent Director | 3yrs | US$279.18k | 0.13% $ 674.7k | |
| Independent Director | 1.2yrs | US$245.44k | 0.043% $ 218.8k |
5.5yrs
Average Tenure
60.5yo
Average Age
Experienced Board: CTEV's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/11 09:27 |
| End of Day Share Price | 2026/06/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Claritev Corporation is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Steven Valiquette | Barclays |
| Glen Santangelo | Barclays |
| Andrew D'Silva | B. Riley Securities, Inc. |